Reevaluating the Accelerated Approval Process for Oncology DrugsWILSON, Wyndham H; SCHENKEIN, David P; JERNIGAN, Cheryl L et al.Clinical cancer research (Print). 2013, Vol 19, Num 11, pp 2804-2809, issn 1078-0432, 6 p.Article

Hydrallmanol A, an interesting diphenyl-p-menthane derivative of mixed biogenetic origin from the hydroid Hydrallmania falcataPATHIRANA, C; ANDERSEN, R. J; WRIGHT, J. C. L et al.Tetrahedron letters. 1989, Vol 30, Num 12, pp 1487-1490, issn 0040-4039, 4 p.Article

Vindesine and high-dose cisplatin in the treatment of advanced non-small-cell lung cancerFUKS, J. Z; PATEL, H; VAN ECHO, D. A et al.Medical and pediatric oncology. 1985, Vol 13, Num 2, pp 73-77, issn 0098-1532Article

Antineoplastic activity of esters and amides of N-[N'-(2-chloroethyl)-N'-nitrosocarbamoyl]-aminoacidsZELLER, W. J; EHRESMANN, K; EISENBRAND, G et al.Journal of cancer research and clinical oncology. 1984, Vol 108, Num 2, pp 249-251, issn 0171-5216Article

DrugsCancer chemotherapy. 1984, Num 6, pp 1-199Article

The antiproliferative effect of suramin on the cancer cell line SW-13 is mediated by the inhibition of transforming growth factor β1 (TGF-β1) : IV meeting of the inter-regional group Abruzzo, Lazio, Molise, Toscana, Umbria of the Italian Society of Pharmacology, Pisa, March 11, 1991DANESI, R; AGEN, C; BERNARDINI, N et al.Pharmacological research. 1992, Vol 25, pp 17-18, issn 1043-6618, SUP1Conference Paper

Circadian tolerance to etoposide and cisplatin as first line treatment for advanced lung carcinomaFOCAN, C; BASTENS, B; DRIESSCHAERT, P et al.Annual review of chronopharmacology. 1990, Vol 7, pp 219-222, issn 0743-9539, 4 p.Conference Paper

The role of dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (dthdPase) in the circadian variation of plasma drug levels of 5-fluorouracil (FUra) and 5-fluorodeoxyuridine (FdUrd) following infusion of FUra or FdUrdDAHER, G. C; HARRIS, B. E; ZHANG, R.-W et al.Annual review of chronopharmacology. 1990, Vol 7, pp 227-230, issn 0743-9539, 4 p.Conference Paper

A ¹H n.m.r. study of the role of the glutamate moiety in the binding of methotrexate to Lactobacillus casei dihydrofolate reductaseANTONJUK, D. J; BIRDSALL, B; CHEUNG, H. T. A et al.British journal of pharmacology. 1984, Vol 81, Num 2, pp 309-315, issn 0007-1188Article

Chronotoxicity and phenotypic variabilityASHKENAZI, I. E; PELEG, L; COHEN-KITAY, Y et al.Annual review of chronopharmacology. 1990, Vol 7, pp 241-244, issn 0743-9539, 4 p.Conference Paper

Sparsomycin analogs. VI: Synthesis and antitumor activity of octylsparsomycin analogsKANATOMO, S; HASE, T; WADA, A et al.Chemical and pharmaceutical bulletin. 1989, Vol 37, Num 3, pp 688-691, issn 0009-2363, 4 p.Article

Physicochemical properties and antitumor activities of chemically modified derivatives of antitumor glucan «grifolan LE» from grifola frondosaADACHI, Y; OHNO, N; OHSAWA, M et al.Chemical and pharmaceutical bulletin. 1989, Vol 37, Num 7, pp 1838-1843, issn 0009-2363, 6 p.Article

Anticancer drugsKANEKO, T.Chimica oggi. 1988, Num 5, pp 11-16, issn 0392-839XArticle

Influence of mitoxantrone on nucleolar function in MDA-MB-231 human breast tumor cell lineGHEGINI, N; SAFA, A. R.Cancer letters. 1987, Vol 37, Num 3, pp 327-336, issn 0304-3835Article

Diminution des troubles cytogénétiques induits par des cytostatiques dans les cellules somatiques de rats immunisés par la vaccine tularémiqueNERSESYAN, A. K; ZIL'FYAN, V. N; KUMKUMADZHYAN, V. A et al.Citologiâ. 1986, Vol 28, Num 4, pp 457-460, issn 0041-3771Article

Investigation of the antitumor activity of new epoxide derivatives. II: N-glycidylated oxo-nitrogen heterocyclesFISCHER, H; MÖLLER, H; BUDNOWSKI, M et al.Arzneimittel-Forschung. 1984, Vol 34, Num 6, pp 663-668, issn 0004-4172Article

Synthesis and retention of methotrexate polyglutamates by human small cell lung cancerCURT, G. A; JOLIVET, J; BAILEY, B. D et al.Biochemical pharmacology. 1984, Vol 33, Num 10, pp 1682-1685, issn 0006-2952Article

Preparation of and drug release from W/O/W type double emulsions containing anticancer agentsFUKUSHIMA, S; JUNI, K; NAKANO, M et al.Chemical and pharmaceutical bulletin. 1983, Vol 31, Num 11, pp 4048-4056, issn 0009-2363Article

Assay and time course of 5-fluorouracil incorporation into RNA of L1210/0 ascites cells in vivoSPEARS, C. P; JASHOVAM SHANI; SHAHINIAN, A. H et al.Molecular pharmacology. 1985, Vol 27, Num 2, pp 302-307, issn 0026-895XArticle

Les antioncogènes = AntioncogenesJUNIEN, C.Transactions of the Zoological Society of London. 1989, Vol 37, Num 9, pp 949-950, issn 0084-5620, 2 p.Conference Paper

Purified colicin as cytotoxic agent of neoplasia: comparative study with crude colicinFARKAS-HIMSLEY, H; YU, H.Cytobios. 1985, Vol 42, Num 167-168, pp 193-207, issn 0011-4529Article

Eribulin MesylateJAIN, Sarika; VAHDAT, Linda T.Clinical cancer research (Print). 2011, Vol 17, Num 21, pp 6615-6622, issn 1078-0432, 8 p.Article

Enhancement of Bik antitumor effect by Bik mutantsLI, Yan M; YONG WEN; ZHOU, Binhua P et al.Cancer research (Baltimore). 2003, Vol 63, Num 22, pp 7630-7633, issn 0008-5472, 4 p.Article

Sixth international symposium on platinum and other metal coordination compounds in cancer chemotherapy : abstractsAnti-cancer drug design. 1991, Vol 6, Num 4, issn 0266-9536, 176 p.Conference Proceedings

High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasmaBEIJNEN, J. H; SMITH, B. R; KEIJER, W. J et al.Journal of pharmaceutical and biomedical analysis. 1990, Vol 8, Num 8-12, pp 789-794, issn 0731-7085, 6 p.Conference Paper